These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 11120395

  • 1. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy.
    Maes M, Capuron L, Ravaud A, Gualde N, Bosmans E, Egyed B, Dantzer R, Neveu PJ.
    Neuropsychopharmacology; 2001 Feb; 24(2):130-40. PubMed ID: 11120395
    [Abstract] [Full Text] [Related]

  • 2. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation.
    Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Meltzer H.
    Mol Psychiatry; 2001 Jul; 6(4):475-80. PubMed ID: 11443537
    [Abstract] [Full Text] [Related]

  • 3. Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.
    Van Gool AR, Van Ojik HH, Kruit WH, Mulder PG, Fekkes D, Bannink M, Scharpé S, Stoter G, Eggermont AM, Maes M, Verkerk R.
    J Interferon Cytokine Res; 2004 Jul; 24(7):411-5. PubMed ID: 15296652
    [Abstract] [Full Text] [Related]

  • 4. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.
    Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, Levrero M, Egyed B, Bosmans E, Meltzer HY, Maes M.
    Psychiatry Res; 2001 Dec 15; 105(1-2):45-55. PubMed ID: 11740974
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.
    Clin Cancer Res; 2000 Apr 15; 6(4):1267-72. PubMed ID: 10778950
    [Abstract] [Full Text] [Related]

  • 6. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C.
    Maes M, Bonaccorso S.
    Acta Psychiatr Scand; 2004 Feb 15; 109(2):126-31. PubMed ID: 14725594
    [Abstract] [Full Text] [Related]

  • 7. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
    Capuron L, Ravaud A, Miller AH, Dantzer R.
    Brain Behav Immun; 2004 May 15; 18(3):205-13. PubMed ID: 15050647
    [Abstract] [Full Text] [Related]

  • 8. Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: relationships with immune-inflammatory markers.
    Maes M, De Meester I, Verkerk R, De Medts P, Wauters A, Vanhoof G, Vandoolaeghe E, Neels H, Scharpé S.
    Psychoneuroendocrinology; 1997 Feb 15; 22(2):65-78. PubMed ID: 9149329
    [Abstract] [Full Text] [Related]

  • 9. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.
    Capuron L, Ravaud A, Dantzer R.
    J Clin Oncol; 2000 May 15; 18(10):2143-51. PubMed ID: 10811680
    [Abstract] [Full Text] [Related]

  • 10. Lowered serum dipeptidyl peptidase IV activity in patients with anorexia and bulimia nervosa.
    van West D, Monteleone P, Di Lieto A, De Meester I, Durinx C, Scharpe S, Lin A, Maj M, Maes M.
    Eur Arch Psychiatry Clin Neurosci; 2000 May 15; 250(2):86-92. PubMed ID: 10853924
    [Abstract] [Full Text] [Related]

  • 11. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy.
    Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ.
    Psychoneuroendocrinology; 2001 Nov 15; 26(8):797-808. PubMed ID: 11585680
    [Abstract] [Full Text] [Related]

  • 12. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol.
    Wichers MC, Kenis G, Koek GH, Robaeys G, Nicolson NA, Maes M.
    J Psychosom Res; 2007 Feb 15; 62(2):207-14. PubMed ID: 17270579
    [Abstract] [Full Text] [Related]

  • 13. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.
    Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R.
    Mol Psychiatry; 2002 Feb 15; 7(5):468-73. PubMed ID: 12082564
    [Abstract] [Full Text] [Related]

  • 14. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
    Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M.
    J Clin Psychopharmacol; 2002 Feb 15; 22(1):86-90. PubMed ID: 11799348
    [Abstract] [Full Text] [Related]

  • 15. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
    Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC.
    Clin Cancer Res; 2000 Oct 15; 6(10):3895-903. PubMed ID: 11051235
    [Abstract] [Full Text] [Related]

  • 16. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
    Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, Soppi E.
    Immunopharmacol Immunotoxicol; 1996 Aug 15; 18(3):337-54. PubMed ID: 8872489
    [Abstract] [Full Text] [Related]

  • 17. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders.
    Igue R, Potvin S, Bah R, Stip E, Bouchard RH, Lipp O, Gendron A, Kouassi E.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug 15; 35(7):1695-8. PubMed ID: 21627977
    [Abstract] [Full Text] [Related]

  • 18. Lower activity of serum peptidases in abstinent alcohol-dependent patients.
    Maes M, Lin A, Bonaccorso S, Vandoolaeghe E, Song C, Goossens F, De Meester I, Degroote J, Neels H, Scharpé S, Janca A.
    Alcohol; 1999 Jan 15; 17(1):1-6. PubMed ID: 9895030
    [Abstract] [Full Text] [Related]

  • 19. CD26/dipeptidyl-peptidase IV and adenosine deaminase serum levels in psoriatic patients treated with cyclosporine, etanercept, and psoralen plus ultraviolet A phototherapy.
    Yıldırım FE, Karaduman A, Pinar A, Aksoy Y.
    Int J Dermatol; 2011 Aug 15; 50(8):948-55. PubMed ID: 21781066
    [Abstract] [Full Text] [Related]

  • 20. Dipeptidyl peptidase IV (DPP IV, CD26) in patients with mental eating disorders.
    Hildebrandt M, Rose M, Mayr C, Arck P, Schüler C, Reutter W, Salama A, Klapp BF.
    Adv Exp Med Biol; 2000 Aug 15; 477():197-204. PubMed ID: 10849747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.